Funds and ETFs Incyte Corporation

INCY

US45337C1027

Name	Weight	AuM	1st Jan change	Investor Rating
AGF U.S. MARKET NEUTRAL ANTI-BETA FUND - USD	14.55%	215 M€	+10.68%	-
FIRST TRUST NYSE ARCA BIOTECHNOLOGY ETF - CAD	2.94%	1 M€	-5.79%	-
LEVERAGE SHARES 1X ARK GENOMIC TRACKER ETP - USD	2.88%	1 M€	0.00%	-
IQ U.S. MID CAP R&D LEADERS ETF - USD	2.10%	4 M€	+20.15%
ASYMSHARES ASYMMETRIC 500 ETF - USD	1.95%	16 M€	-3.37%
LEVERAGE SHARES 3X LONG BIOTECHNOLOGY ETP SECURITIES - USD	1.68%	0 M€	0.00%	-
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD HEDGED	1.65%	2 M€	+6.77%
FIRST TRUST ALPHADEX U.S. HEALTH CARE SECTOR INDEX ETF - CAD	1.54%	8 M€	+2.44%
LEVERAGE SHARES -3X SHORT BIOTECHNOLOGY ETP SECURITIES - USD	1.50%	0 M€	0.00%	-
RBC QUANT U.S. EQUITY LEADERS ETF - CAD	0.41%	13 M€	-.--%	-
RBC QUANT U.S. EQUITY LEADERS ETF (D) - CAD	0.41%	4 M€	-.--%	-
RBC QUANT U.S. EQUITY LEADERS ETF - USD	0.41%	3 M€	+15.16%	-
NOMURA NEXT FUNDS INTERNATIONAL EQUITY MSCI-KOKUSAI (YEN-HEDGED) ETF - JPY	0.37%	18 M€	+3.79%	-
HARTFORD DISCIPLINED US EQUITY ETF - USD	0.29%	105 M€	+6.17%
SYNTAX STRATIFIED TOTAL MARKET II ETF - USD	0.20%	8 M€	+3.41%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET HEDGED ETF - USD	0.20%	33 M€	+0.25%	-
SYNTAX STRATIFIED U.S. TOTAL MARKET ETF - USD	0.20%	18 M€	+3.41%	-
ARMOR US EQUITY INDEX ETF - USD	0.17%	9 M€	-.--%	-
HARTFORD MULTIFACTOR US EQUITY ETF - USD	0.17%	393 M€	+5.25%
ADVOCATE RISING RATE HEDGE ETF - USD	0.14%	5 M€	-72.95%	-
ADAPTIVE RH TACTICAL OUTLOOK ETF - USD	0.08%	9 M€	+6.26%	-
IMGP RBA RESPONSIBLE GLOBAL ALLOCATION ETF - USD	0.08%	7 M€	+0.11%	-
AMUNDI MSCI USA ESG LEADERS SELECT UCITS ETF DR (C) - EUR HEDGED	0.07%	219 M€	+17.17%	-
AMUNDI MSCI USA ESG LEADERS SELECT - UCITS ETF DR (C) - USD	0.07%	1,448 M€	-.--%	-

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (85.6%); - royalties (14.2%); - income from research and cooperation agreements (0.2%).

Sector

Pharmaceuticals

Calendar

2024-04-30 - Q1 2024 Earnings Release

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for Incyte Corporation

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

51.68 USD

Average target price

75.2 USD

Spread / Average Target

+45.51%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Biopharmaceuticals

	1st Jan change	Capi.
INCYTE CORPORATION	-17.69%	11.6B
CSL LIMITED	-4.66%	86.13B
SAMSUNG BIOLOGICS CO.,LTD.	+1.32%	39.82B
BIOGEN INC.	-19.27%	30.42B
UCB	+57.86%	25.23B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.	-43.00%	11.51B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD.	-9.14%	11.95B
SWEDISH ORPHAN BIOVITRUM AB	+5.24%	8.71B
INNOVENT BIOLOGICS, INC.	-8.42%	8.12B
INTRA-CELLULAR THERAPIES, INC.	+2.29%	7.72B

Biopharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
51.68 ^USD	+0.98%		-1.28%	-17.69%

Apr. 24	Oppenheimer Adjusts Incyte Price Target to $84 From $92, Maintains Outperform Rating	MT
Apr. 23	Transcript : Escient Pharmaceuticals, Inc., Incyte Corporation - M&A Call